New crystalline forms, new pharmaceutical composition and dose regimen of a dipeptidyl-peptidase i inhibitor for the treatment of patients with bronchiectasis or other dpp-i mediated diseases

Abstract

The present invention relates to the dipeptidyl‑peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.